Drugs / ICP-B208
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | China (NMPA) | — | cholangiocarcinoma, susceptibility to | — | “公司已经于2026年3月中在中国提交ICP-B208 的IND申请。” innocarepharma.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07617493 | Jul 2026 → Dec 2030 expected | neoplasm | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-07 | Beijing InnoCare Pharma Tech Co., Ltd. | Regulatory 诺诚健华自主研发的CDH17靶向ADC创新药ICP B208获批临床 innocarepharma.com ↗
2026年5月7日，中国北京——诺诚健华（上交所代码：688428；香港联交所代码：09969）宣布，公司自主研发的靶向CDH17的新型ADC创新药ICP-B208获国家药品监督管理局（NMPA）药品审评中心（CDE）批准开展临床研究。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-07 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华自主研发的CDH17靶向ADC创新药ICP B208获批临床 innocarepharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICP-B208 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07617493 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07617493 ↗ |